Keryx Biopharmaceuticals is a commercial stage biopharmaceutical company focused on bringing medicines to people with kidney disease. Co.'s marketed product, Auryxia (ferric citrate) tablets, is an orally available, absorbable, iron-based medicine. Auryxia is used for the control of serum phosphorus levels in patients with chronic kidney disease (CKD), on dialysis. Auryxia is also for the treatment of iron deficiency anemia in adults with CKD, not on dialysis. Ferric citrate is also approved in Japan under the trade name Riona and marketed by Co.'s Japanese partner, Japan Tobacco, Inc. and its subsidiary, Torii Pharmaceutical Co., Ltd., and approved in Europe as Fexeric. We show 36 historical shares outstanding datapoints in our coverage of KERX's shares outstanding history.
Understanding the changing numbers of KERX shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like KERX versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching KERX by allowing them to research KERX shares outstanding history
as well as any other stock in our coverage universe. |
Free KERX Email Alerts:
Video: Shares Outstanding Importance
